Ocular Therapeutix (NASDAQ: OCUL) granted inducement equity awards to new SVP, Head of HR, Amy Ricca, under its 2019 Inducement Stock Incentive Plan and Nasdaq Rule 5635(c)(4).
The grants include options for 75,000 shares at $9.28 and 25,000 restricted stock units with multi-year vesting schedules.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – OCUL
-3.58%
2 alerts
-3.58%Session close to close
$2.08BMarket Cap
2.20KVolume
In the May 15 session, OCUL declined 3.58%, reflecting a moderate negative market reaction.
Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
This announcement details inducement equity awards tied to a senior HR hire, including 75,000 stock ...
Analysis
This announcement details inducement equity awards tied to a senior HR hire, including 75,000 stock options at a $9.28 exercise price and 25,000 RSUs, with long-term vesting schedules. Context includes recent Phase 3 progress, a solid cash position reported in early May, and an effective S-3ASR shelf registration filed on September 30, 2025. Investors may track future grants, clinical milestones, and any securities offered under the shelf as key indicators of capital strategy and execution.
Key Figures
Current share price:$9.5052-week high:$16.44Stock options granted:75,000 shares+5 more
8 metrics
Current share price$9.50OCUL pre-news market context
52-week high$16.44OCUL 52-week range high
Stock options granted75,000 sharesNon-statutory stock option inducement award
RSUs granted25,000 sharesRestricted stock unit inducement awards
Option exercise price$9.28 per shareEqual to OCUL closing price on May 11, 2026
Option term10 yearsTen-year term for inducement stock option
Option vesting period4 years25% after one year, remainder monthly over next three years
RSU vesting period3 yearsEqual annual installments on first three anniversaries of grant
Planned participation at scientific and investor conferences with Phase 3 data presentations.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent news, including clinical and conference updates, often coincided with modestly negative or muted price reactions, even when operationally positive.
Recent Company History
Over the past few weeks, Ocular Therapeutix announced multiple developments, including inducement equity grants to new hires on May 4, 2026, first-quarter 2026 financial results with positive Phase 3 SOL-1 data and strong cash of $666.7M, and enrollment of the first patient in the long-term SOL-X extension trial. The company also flagged its earnings date and detailed a busy May conference schedule. Despite these updates, share reactions around several announcements were slightly negative, framing today’s HR-related inducement grants against a backdrop of active clinical progress.
Key Terms
nasdaq listing rule 5635(c)(4), non-statutory stock option, restricted stock unit, exercise price, +2 more
6 terms
nasdaq listing rule 5635(c)(4)regulatory
"inducement grants under Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
non-statutory stock optionfinancial
"consist of a non-statutory stock option award to purchase up to 75,000 shares"
A non-statutory stock option is a company-granted right that lets a person buy shares later at a set price but does not receive special tax-favored treatment under tax law. It matters to investors because when the option is used the holder usually pays ordinary income tax on the gain and the company records compensation cost and issues new shares, which can reduce existing owners’ percentage ownership—think of it like a coupon to buy stock that creates a taxable event and some dilution.
restricted stock unitfinancial
"and restricted stock unit awards representing the right to receive an aggregate"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
exercise pricefinancial
"stock option award has an exercise price of $9.28 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vestingfinancial
"the stock option award has a ten-year term and vests over four years, with 25%"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
inducement stock incentive planfinancial
"under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq"
An inducement stock incentive plan is a program that gives newly hired employees or executives shares or stock-based awards as a reward for joining a company and to encourage them to stay and perform. For investors, it matters because these grants can dilute existing shareholders, increase reported compensation costs, and signal how a company is investing in talent—similar to a signing bonus mixed with a stake in the business.
BEDFORD, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to Ms. Amy Ricca, the Company’s new SVP, Head of HR. The awards were made as an inducement material to the recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement equity awards granted to Ms. Ricca were effective as of May 11, 2026 and consist of a non-statutory stock option award to purchase up to 75,000 shares of Ocular’s common stock and restricted stock unit awards representing the right to receive an aggregate of 25,000 shares of Ocular’s common stock. Ms. Ricca’s stock option award has an exercise price of $9.28 per share, equal to the closing price of Ocular’s common stock on The Nasdaq Global Market on the effective date of grant. The stock option award has a ten-year term and vests over four years, with 25% of the original number of shares vesting on the one-year anniversary of the date of grant, and the remainder vesting in equal monthly installments over the three years after such date, subject to the recipient’s continued service to Ocular through the applicable vesting dates. The restricted stock unit awards vest over three years, in equal annual installments on the first, second and third anniversaries of the date of grant, subject to the recipient’s continued service to Ocular through the applicable vesting dates.
The inducement awards are subject to the terms and conditions of the award agreements covering the grants and Ocular’s 2019 Inducement Stock Incentive Plan.
About Ocular Therapeutix, Inc. Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.
Follow the Company on its website, LinkedIn, or X.
DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media Ocular Therapeutix, Inc. Bill Slattery Vice President, Investor Relations bslattery@ocutx.com
FAQ
What inducement equity awards did Ocular Therapeutix (OCUL) grant to Amy Ricca in May 2026?
Ocular Therapeutix granted Amy Ricca a stock option for 75,000 shares and 25,000 restricted stock units. According to Ocular, these awards were granted under the 2019 Inducement Stock Incentive Plan as a material inducement to her joining as SVP, Head of HR.
What is the exercise price and term of the new Ocular Therapeutix (OCUL) stock options granted to Amy Ricca?
The stock options have an exercise price of $9.28 per share and a ten-year term. According to Ocular, the price equals the May 11, 2026 Nasdaq Global Market closing price and the options vest over four years, subject to continued service.
How do the Ocular Therapeutix (OCUL) inducement stock options granted in May 2026 vest over time?
The options vest 25% on the first anniversary of grant, then monthly over the next three years. According to Ocular, vesting requires Amy Ricca’s continued service, aligning long-term incentives with company performance and employee retention goals.
What is the vesting schedule for the 25,000 RSUs granted by Ocular Therapeutix (OCUL) to Amy Ricca?
The 25,000 restricted stock units vest in three equal annual installments over three years. According to Ocular, vesting occurs on the first, second, and third anniversaries of the grant date, contingent on continued employment throughout each vesting date.
Why did Ocular Therapeutix (OCUL) use Nasdaq Listing Rule 5635(c)(4) for these inducement grants?
The awards were structured as inducement grants material to Amy Ricca’s acceptance of employment. According to Ocular, they were issued under Nasdaq Listing Rule 5635(c)(4) and the 2019 Inducement Stock Incentive Plan, rather than under the company’s shareholder-approved plans.
